|
Rubella Vaccine
Inventor:
Stanley Plotkin
Tech ID:
PS-111
Description:
The RA 27/3 strain of rubella virus was developed at The
Wistar Institute. The seed stock from RA 27/3 has been successfully
used worldwide since the 1970's as a vaccine for the prevention
of rubella infection. This vaccine has been administered alone and
as part of a combination vaccine (e.g. MMR; measles, mumps, rubella
vaccine).
The Wistar
Institute has maintained seed stocks of
the RA/ 27/3 strain of rubella for use
in production of vaccines. These vaccines
have been licensed to regional public
health agencies and to for-profit companies
who are developing vaccines for local
distribution, particularly in Asia and
South America.
Key Words:
Vaccine, rubella
Applications
and Advantages: The RA 27/3 seed stock may be used
for development of vaccines that may be available at a lower cost
than those vaccines produced by the major pharmaceutical companies.
Intellectual
Property Status: The Wistar Institute
can provide the proprietary biological
material used to make the vaccines.
Licensing Opportunity:
The RA27/3 strain of rubella virus is
available for licensing outside of the
United States.
Contact:
Meryle
J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org
Last Updated: Aug-02
|
